Last 20 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.01 | 39.84 | 14.21 | 2.31 | 0.55 | 58.68 | 2.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -32.1% | +392.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | -0.59 | — | — | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | -0.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -457.6% | -2120.0% | -188.9% | -92.1% | -91.9% | -185.0% | -67.1% | — | — | — | — | — | -5.6% | 0.6% | -0.0% | 0.9% | 0.3% | 0.0% | -0.2% | -0.2% | -0.1% |
| — | -1046.0% | -181.5% | — | — | — | — | — | — | — | — | — | -2278.8% | +1642.7% | +96.0% | +536.3% | +401.2% | — | — | — | — | |
| ROA | -236.4% | -80.3% | -46.3% | -46.9% | -37.5% | -35.5% | -31.1% | -58.7% | -422.3% | -48.2% | -31.1% | -31.6% | -4.7% | 0.6% | -0.0% | 0.8% | 0.3% | 0.0% | -0.2% | -0.2% | -0.1% |
| — | -126.2% | -48.9% | +20.2% | +91.1% | +26.3% | -0.0% | -85.7% | -8795.6% | -8149.3% | -722220.9% | -4109.7% | -1978.1% | +1517.8% | +98.0% | +477.1% | +399.9% | — | — | — | — | |
| ROIC | — | — | — | — | — | -1278.4% | — | — | — | — | — | — | -3.3% | -0.4% | -0.0% | -0.7% | -0.2% | -0.1% | -0.2% | -0.3% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | -2054.2% | -321.1% | +95.4% | -159.9% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 32.05 | 1.50 | 0.18 | 0.07 | 30.82 | 1.35 | — | — | — | — | — | 0.79 | 0.08 | 0.06 | — | — | — | — | — | — |
| — | +4.0% | +11.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 0.04 | — | — | 0.02 | — | — | — | — | — | — | — | — | — | 12.95 | — | 0.55 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.41 | 0.94 | 1.00 | 2.41 | 3.97 | 2.44 | 3.22 | 0.64 | 0.85 | 0.98 | 1.72 | 2.27 | 2.25 | 12.26 | 0.06 | 5.49 | 0.32 | 0.33 | 0.62 | 1.17 | 13.00 |
| — | -61.4% | -68.9% | +276.8% | +366.6% | +148.7% | +87.4% | -71.8% | -62.1% | -92.0% | +2757.3% | -58.7% | +594.4% | +3576.1% | -90.2% | +369.3% | -97.5% | — | — | — | — | |
| Quick Ratio | 2.41 | 0.94 | 1.00 | 2.41 | 3.97 | 2.44 | 3.22 | 0.64 | 0.85 | 0.98 | 1.72 | 2.27 | 2.25 | 12.26 | 0.06 | 5.49 | 0.32 | 0.33 | 0.62 | 1.17 | 13.00 |
| — | -61.4% | -68.9% | +276.8% | +366.6% | +148.7% | +87.4% | -71.8% | -62.1% | -92.0% | +2757.3% | -58.7% | +594.4% | +3576.1% | -90.2% | +369.3% | -97.5% | — | — | — | — | |
| Interest Coverage | -915.08 | — | — | -734.33 | — | — | -191.78 | — | -227.04 | -742.50 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 20 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLXN stock.
Silexion Therapeutics Ltd.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Silexion Therapeutics Ltd.'s business trajectory between earnings reports.